Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
base editing
Biotech
Lilly preps gene editor for ph. 2 after strong cholesterol cuts
A one-time infusion of a Verve base editor led to a sustained 62% drop in cholesterol, clearing the bar set by approved PCSK9 inhibitors.
Darren Incorvaia
May 25, 2026 8:45am
Beam rejigs deal to retain technology amid partner's dissolution
Mar 6, 2026 8:20am
Inside Beam's 'big push' for in vivo gene editing
Jan 21, 2026 7:52am
Custom gene editor fixes mutation causing deadly disease in mice
Sep 11, 2025 1:48pm
NIH gene editing fixes Tay-Sachs mutation in mice
Aug 19, 2025 4:22pm
Verve posts clean PCSK9 editor profile, teeing up Lilly decision
Apr 14, 2025 7:00am
